Program
Nigella sativa oil
Also written as “NP101”, “NP-101” and “NP101 Sumatriptan Iontophoretic Transdermal Patch”.
Its studies are mostly in Migraine Disorders · Gastro-enteropancreatic neuroendocrine tumor · COVID-19, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Teva Pharmaceutical Industries | 50 open or running | phase 3since Nov 14, 2008 | Jul 21, 2008 | none ahead |
| Novatek Pharmaceuticals | 21 open or running | phase 3since Oct 6, 2026 | Mar 23, 2023 | Dec 2029phase 3 · NCT07935928 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2008First studies: 2 phase 1 studies in Migraine DisordersNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00720018, NCT00723983
- Nov 14, 2008Phase 3 study in Migraine DisordersTeva Pharmaceutical Industries · NCT00792103 · 198 enrolled · United States
- Dec 10, 2008Phase 3 study in Migraine DisordersTeva Pharmaceutical Industries · NCT00806546 · 514 enrolled · United States
- Jun 22, 2011Phase 1 study in Compare Bioequivalence Patches Previously Used in the NP101-007 StudyTeva Pharmaceutical Industries · NCT01381796 · 63 enrolled · United States
- Mar 23, 2023Novatek Pharmaceuticals’ first study: phase 2 study in COVID-19New to Novatek PharmaceuticalsNovatek Pharmaceuticals · NCT05785390 · 170 enrolled · United States
- Oct 6, 2026Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsPhase 3 reachedNovatek Pharmaceuticals · NCT07935928 · 381 planned
Ahead
- Dec 2029Primary completion: phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsNovatek Pharmaceuticals · NCT07935928
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07935928Gastroenteropancreatic Neuroendocrine Tumors | 3 | Not yet recruiting | Novatek Pharmaceuticals | Dec 2029 | 381 |
| NCT05785390COVID-19 · United States | 2 | Terminated | Novatek Pharmaceuticals | May 9, 2025 | 170 |
| NCT01381796Compare Bioequivalence Patches Previously Used in the NP101-007 Study · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2010 | 63 |
| NCT00806546Migraine Disorders · United States | 3 | Completed | Teva Pharmaceutical Industries | May 2011 | 514 |
| NCT00792103Migraine Disorders · United States | 3 | Completed | Teva Pharmaceutical Industries | Sep 2010 | 198 |
| NCT00723983Migraine Disorders · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2009 | 23 |
| NCT00720018Migraine Disorders · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2008 | 4 |
How it is read
Names in the registry
- “NP101”, 3 entries
- “NP-101”, 2 entries
- “NP101 Sumatriptan Iontophoretic Transdermal Patch”, 1 entry
- “NP101 Study Patch”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 4 studies
- Gastro-enteropancreatic neuroendocrine tumor, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.